Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.
The aim of this study was to assess the glucose-lowering and lipid-modifying effects, and safety profile of lobeglitazone, a novel peroxisome proliferator-activated receptor- γ agonist, compared to placebo as a monotherapy in patients with type 2 diabetes.In this 24-week, multicenter, randomized, do...
Main Authors: | Sin Gon Kim, Doo Man Kim, Jeong-Taek Woo, Hak Chul Jang, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yong Soo Park, Sang Jin Kim, Dong Seop Choi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3988010?pdf=render |
Similar Items
-
Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
by: Sorim Choung, et al.
Published: (2018-01-01) -
A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
by: Bo-Yeon Kim, et al.
Published: (2022-11-01) -
Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages
by: Dabin Jeong, et al.
Published: (2021-10-01) -
Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver.
by: Hye-Young Seo, et al.
Published: (2023-01-01) -
Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
by: Hye-Young Seo, et al.
Published: (2023-01-01)